Prof. Dr. Daniel Ricklin

Ekaterina Umnyakova, Alexander J. Lander, & Daniel Ricklin. (2025). Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Trends in Pharmacological Sciences, 46. https://doi.org/10.1016/j.tips.2025.07.007

Felsch, Jannes, Jacquemai, Simona, Suthagar, Shugirshan, Zhao, Haijie, Lander, Alexander John, Rabbani, Said, Ricklin, Daniel, & Umnyakova, Ekaterina. (2025). Assay System Based on Metabolic Glycoengineering‐Enabled Click Chemistry for the Efficient Evaluation of Complement‐Regulatory Peptide Coatings on Endothelial Cells [Journal-article]. Advanced Materials Interfaces. https://doi.org/10.1002/admi.202500350

Kinzi, Jonny, Hussner, Janine, Seibert, Isabell, Rysz, Marta, Taggi, Valerio, Zuercher, Simone, Tillmann, Annika, Schwardt, Oliver, Oswald, Stefan, Ricklin, Daniel, & Meyer zu Schwabedissen, Henriette E. (2025). Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1. Pharmacology Research and Perspectives, 13(4). https://doi.org/10.1002/prp2.70133

Rysz, Marta A., Schäfer, Anima M., Kinzi, Jonny, Paloumpis, Nikolaos, In-Albon, Katja, Schmidlin, Seraina, Seibert, Isabell, Ricklin, Daniel, & Meyer zu Schwabedissen, Henriette E. (2025). Erlotinib—A substrate and inhibitor of OATP2B1: pharmacokinetics and CYP3A-mediated metabolism in rSlco2b1−/− and SLCO2B1+/+ rats [Journal-article]. Drug Metabolism and Disposition, 53(5), 100069. https://doi.org/10.1016/j.dmd.2025.100069

Sommer-Plüss, Carla Johanna, Leiggener, Céline, Nikci, Elira, Mancuso, Riccardo Vincenzo, Rabbani, Said, Lamers, Christina, & Ricklin, Daniel. (2025). Determining Ligand Binding and Specificity Within the β2-Integrin Family with a Novel Assay Platform [Journal-article]. Biomolecules, 15(2), 238. https://doi.org/10.3390/biom15020238

Ricklin, Daniel. (2024). Complement-targeted therapeutics: Are we there yet, or just getting started? [Journal-article]. European Journal of Immunology, 54(12). https://doi.org/10.1002/eji.202350816

Kinzi, Jonny, Hussner, Janine, Seibert, Isabell, Vythilingam, Mirubagini, Vonwyl, Celina, Gherardi, Clarisse, Detampel, Pascal, Schwardt, Oliver, Ricklin, Daniel, & Meyer zu Schwabedissen, Henriette E. (2024). Impact of OATP2B1 on Pharmacokinetics of Atorvastatin Investigated in rSlco2b1-Knockout and SLCO2B1-Knockin Rats. Drug Metabolism and Disposition, 52(9), 957–965. https://doi.org/10.1124/dmd.124.001686

Rysz, Marta, Schäfer, Anima M., Paloumpis, Nikolaos, Kinzi, Jonny, Brecht, Karin, Seibert, Isabell, Schmidlin, Seraina, In-Albon, Katja, Ricklin, Daniel, & Meyer zu Schwabedissen, Henriette E. (2024). Humanization of SLCO2B1 in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420 [Journal-article]. Journal of Pharmacology and Experimental Therapeutics, 389(1), 87–95. https://doi.org/10.1124/jpet.123.001884

van Beek, Anna E., Jeanguenat, Hannah, Häberli, Cécile, Pouw, Richard B., Lamers, Christina, Pál, Gábor, Gál, Péter, Schmidt, Christoph Q., Ricklin, Daniel, & Keiser, Jennifer. (2024). Praziquantel and factor H recruitment differentially affect the susceptibility of Schistosoma mansoni to complement-mediated damage. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1474358

Conti, Gabriele, Bärenwaldt, Anne, Rabbani, Said, Mühlethaler, Tobias, Sarcevic, Mirza, Jiang, Xiaohua, Schwardt, Oliver, Ricklin, Daniel, Pieters, Roland J., Läubli, Heinz, & Ernst, Beat. (2023). Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation. Angewandte Chemie - International Edition, 62(52). https://doi.org/10.1002/anie.202314280

Rysz, Marta A., Kinzi, Jonny, Schäfer, Anima M., In-Albon, Katja, Zürcher, Simone, Schmidlin, Seraina, Seibert, Isabell, Schwardt, Oliver, Ricklin, Daniel, & Meyer zu Schwabedissen, Henriette E. (2023). Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method. Journal of Pharmaceutical and Biomedical Analysis, 236. https://doi.org/10.1016/j.jpba.2023.115716

Bechtler, Clément, Barneoud-Rousset, Ouliana, Pang, Lijuan, Martin, Kea, König, Katrin F, Hänggi, Pascal, Pearson, Nick, & Ricklin, Daniel. (2023). Optimized synthesis, polymer conjugation, and proof-of-concept studies of the gd-IgA1 epitope for antibody-scavenging therapies in IgA nephropathy. Chemical Biology and Drug Design, 102(3), 580–586. https://doi.org/10.1111/cbdd.14258

Lamers, Christina, Ricklin, Daniel, & Lambris, John D. (2023). Complement-targeted therapeutics: An emerging field enabled by academic drug discovery. American Journal of Hematology, 98(S4), S82–S89. https://doi.org/10.1002/ajh.26875

Bechtler, Clément, Koutsogiannaki, Sophia, Umnyakova, Ekaterina, Hamid, Amal, Gautam, Avneesh, Sarigiannis, Yiannis, Pouw, Richard B., Lamers, Christina, Rabbani, Said, Schmidt, Christoph Q., Lambris, John D., & Ricklin, Daniel. (2023). Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6. Acta Biomaterialia, 155, 123–138. https://doi.org/10.1016/j.actbio.2022.10.055

Golomingi, M., Kohler, J., Lamers, C., Pouw, R. B., Ricklin, D., Dobó, J., Gál, P., Pál, G., Kiss, B., Dopler, A., Schmidt, C. Q., Hardy, E. T., Lam, W., & Schroeder, V. (2023). Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1226832

Lamers, Christina, Xue, Xiaoguang, Smiesko, Martin, van Son, Henri, Wagner, Bea, Berger, Nadja, Sfyroera, Georgia, Gros, Piet, Lambris, John D, & Ricklin, Daniel. (2022). Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Nature Communications, 13(1), 5519. https://doi.org/10.1038/s41467-022-33003-7

Lamers, Christina, Mastellos, Dimitrios C, Ricklin, Daniel, & Lambris, John D. (2022). Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 43(8), 629–640. https://doi.org/10.1016/j.tips.2022.01.004

Li, Bojun, Bechtler, Clément, Jenny, Lorenz, Ricklin, Daniel, & Schroeder, Verena. (2022). Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners. Research and Practice in Thrombosis and Haemostasis, 6(5), e12766. https://doi.org/10.1002/rth2.12766

Girardi, Benedetta, Manna, Martina, Van Klaveren, Sjors, Tomašič, Tihomir, Jakopin, Žiga, Leffler, Hakon, Nilsson, Ulf J, Ricklin, Daniel, Mravljak, Janez, Schwardt, Oliver, & Anderluh, Marko. (2022). Selective Monovalent Galectin-8 Ligands Based on 3-Lactoylgalactoside. ChemMedChem, 17(3), e202100514. https://doi.org/10.1002/cmdc.202100514

Girardi, B., Manna, M., Van Klaveren, S., Tomašič, T., Jakopin, Ž., Leffler, H., Nilsson, U. J., Ricklin, D., Mravljak, J., Schwardt, O., & Anderluh, M. (2022). Front Cover: Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside (ChemMedChem 3/2022) [Journal-article]. ChemMedChem, 17(3). https://doi.org/10.1002/cmdc.202200044

Mastellos, Dimitrios C, Ricklin, Daniel, Sfyroera, Georgia, & Sahu, Arvind. (2022). From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clinical Immunology, 235, 108785. https://doi.org/10.1016/j.clim.2021.108785

Pouw, Richard B, & Ricklin, Daniel. (2021). Tipping the balance: intricate roles of the complement system in disease and therapy. Seminars in Immunopathology, 43(6), 757–771. https://doi.org/10.1007/s00281-021-00892-7

Ricklin, Daniel, & Pouw, Richard B. (2021). Complement & disease: out of the shadow into the spotlight. Seminars in Immunopathology, 43(6), 755–756. https://doi.org/10.1007/s00281-021-00897-2

Hevey, Rachel, Pouw, Richard B, Harris, Claire, & Ricklin, Daniel. (2021). Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. British Journal of Pharmacology, 178(14), 2802–2822. https://doi.org/10.1111/bph.15307

Zwarthoff, Seline A, Widmer, Kevin, Kuipers, Annemarie, Strasser, Jürgen, Ruyken, Maartje, Aerts, Piet C, de Haas, Carla J C, Ugurlar, Deniz, den Boer, Maurits A, Vidarsson, Gestur, van Strijp, Jos A G, Gros, Piet, Parren, Paul W H I, van Kessel, Kok P M, Preiner, Johannes, Beurskens, Frank J, Schuurman, Janine, Ricklin, Daniel, & Rooijakkers, Suzan H M. (2021). C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases. Proceedings of the National Academy of Sciences of the United States of America, 118(26), 1–12. https://doi.org/10.1073/pnas.2102787118

Schwardt, Oliver, Lamers, Christina, Bechtler, Clément, & Ricklin, Daniel. (2021). Therapeutic peptides as emerging options to restore misguided host defence and homeostasis: From teaching to concept to clinic. Chimia, 75(6), 495–499. https://doi.org/10.2533/chimia.2021.495

Lamers, Christina, Plüss, Carla Johanna, & Ricklin, Daniel. (2021). The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. Frontiers in Immunology, 12, 662164. https://doi.org/10.3389/fimmu.2021.662164

Dopler, Arthur, Stibitzky, Selina, Hevey, Rachel, Mannes, Marco, Guariento, Mara, Höchsmann, Britta, Schrezenmeier, Hubert, Ricklin, Daniel, & Schmidt, Christoph Q. (2021). Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces. Frontiers in Immunology, 12, 615748. https://doi.org/10.3389/fimmu.2021.615748

Kroezen, Blijke, Conti, Gabriele, Girardi, Benedetta, Cramer, Jonathan, Jiang, Xiaohua, Rabbani, Said, Müller, Jennifer, Kokot, Maja, Luisoni, Enrico, Ricklin, Daniel, Schwardt, Oliver, & Ernst, Beat. (2020). A Potent Mimetic of the Siglec-8 Ligand 6’-Sulfo-Sialyl Lewisx. ChemMedChem, 15(18), 1706–1719. https://doi.org/10.1002/cmdc.202000417

Baas, Inge, Delvasto-Nuñez, Laura, Ligthart, Peter, Brouwer, Conny, Folman, Claudia, Reis, Edimara S., Ricklin, Daniel, Lambris, John D., Wouters, Diana, de Haas, Masja, Jongerius, Ilse, & Zeerleder, Sacha S. (2020). Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica, 105(2), e57–e60. https://doi.org/10.3324/haematol.2019.216028

Hughes, Sarah, Gumas, Justin, Lee, Rebecca, Rumano, Merita, Berger, Nadja, Gautam, Avneesh Kumar, Sfyroera, Georgia, Chan, Anna Lorena, Gnanaguru, Gopalan, Connor, Kip M., Kim, Benjamin J., Dunaief, Joshua L., Ricklin, Daniel, Hajishengallis, George, Yancopoulou, Despina, Reis, Edimara S., Mastellos, Dimitrios C., & Lambris, John D. (2020). Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 214, 108391. https://doi.org/10.1016/j.clim.2020.108391

Olcina, Monica M., Kim, Ryan K., Balanis, Nikolas G., Li, Caiyun Grace, von Eyben, Rie, Graeber, Thomas G., Ricklin, Daniel, Stucki, Manuel, & Giaccia, Amato J. (2020). Intracellular C4BPA Levels Regulate NF-κB-Dependent Apoptosis. iScience, 23(10), 101594. https://doi.org/10.1016/j.isci.2020.101594

Mastellos, Dimitrios C., Blom, Anna M., Connolly, E. Sander, Daha, Mohamed R., Geisbrecht, Brian V., Ghebrehiwet, Berhane, Gros, Piet, Hajishengallis, George, Holers, V. Michael, Huber-Lang, Markus, Kinoshita, Taroh, Mollnes, Tom E., Montgomery, Robert A., Morgan, B. Paul, Nilsson, Bo, Pio, Ruben, Ricklin, Daniel, Risitano, Antonio M., Taylor, Ronald P., et al. (2019). Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1). Nature Immunology, 20(11), 1556. https://doi.org/10.1038/s41590-019-0531-x

Lombardi, Elisabetta, Matte, Alessandro, Risitano, Antonio M., Ricklin, Daniel, Lambris, John D., De Zanet, Denise, Jokiranta, Sakari T., Martinelli, Nicola, Scambi, Cinzia, Salvagno, Gianluca, Bisoffi, Zeno, Colato, Chiara, Siciliano, Angela, Bortolami, Oscar, Mazzuccato, Mario, Zorzi, Francesco, De Marco, Luigi, & De Franceschi, Lucia. (2019). Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica, 104(5), 919–928. https://doi.org/10.3324/haematol.2018.198622

Mastellos, Dimitrios C., Blom, Anna M., Connolly, E. Sander, Daha, Mohamed R., Geisbrecht, Brian V., Ghebrehiwet, Berhane, Gros, Piet, Hajishengallis, George, Holers, V. Michael, Huber-Lang, Markus, Kinoshita, Taroh, Mollnes, Tom E., Montgomery, Robert A., Morgan, B. Paul, Nilsson, Bo, Pio, Ruben, Ricklin, Daniel, Risitano, Antonio M., Taylor, Ronald P., et al. (2019). ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 20(11), 1409–1413. https://doi.org/10.1038/s41590-019-0503-1

Mastellos, Dimitrios C., Ricklin, Daniel, & Lambris, John D. (2019). Clinical promise of next-generation complement therapeutics. Nature Reviews. Drug Discovery, 18(9), 707–729. https://doi.org/10.1038/s41573-019-0031-6

Ricklin, Daniel, Mastellos, Dimitrios C, & Lambris, John D. (2019). Therapeutic targeting of the complement system. Nature Reviews. Drug Discovery, DOI:10. https://doi.org/10.1038/s41573-019-0055-y

van Griensven, Martijn, Ricklin, Daniel, Denk, Stephanie, Halbgebauer, Rebecca, Braun, Christian K., Schultze, Anke, Hönes, Felix, Koutsogiannaki, Sofia, Primikyri, Alexandra, Reis, Edimara, Messerer, David, Hafner, Sebastian, Radermacher, Peter, Biglarnia, Ali-Reza, Resuello, Ranillo R. G., Tuplano, Joel V., Mayer, Benjamin, Nilsson, Kristina, Nilsson, Bo, et al. (2019). Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock, 51(1), 78–87. https://doi.org/10.1097/shk.0000000000001127

Devaurs, Didier, Papanastasiou, Malvina, Antunes, Dinler A., Abella, Jayvee R., Moll, Mark, Ricklin, Daniel, Lambris, John D., & Kavraki, Lydia E. (2018). Native State of Complement Protein C3d Analysed via Hydrogen Exchange and Conformational Sampling. International Journal of Computational Biology and Drug Design, 11(1-2), 90–113. https://doi.org/10.1504/ijcbdd.2018.090834

Harris, Claire L., Pouw, Richard B., Kavanagh, David, Sun, Ruyue, & Ricklin, Daniel. (2018). Developments in anti-complement therapy; from disease to clinical trial. Molecular immunology, 102, 89–119. https://doi.org/10.1016/j.molimm.2018.06.008

Reis, Edimara S., Mastellos, Dimitrios C., Ricklin, Daniel, Mantovani, Alberto, & Lambris, John D. (2018). Complement in cancer: untangling an intricate relationship. Nature Reviews. Immunology, 18(1), 5–18. https://doi.org/10.1038/nri.2017.97

Ricklin, Daniel, Mastellos, Dimitrios C., Reis, Edimara S., & Lambris, John D. (2018). The renaissance of complement therapeutics. Nature Reviews Nephrology, 14(1), 26–47. https://doi.org/10.1038/nrneph.2017.156

Yuan, Xiaopeng, Yang, Mingjuan, Chen, Xiang, Zhang, Xuhua, Sukhadia, Shrey, Musolino, Najia, Bao, Huijing, Chen, Tingtao, Xu, Chen, Wang, Qirui, Santoro, Stephen, Ricklin, Daniel, Hu, Jia, Lin, Ruihe, Yang, Wei, Li, Zhijun, Qin, Weijun, Zhao, Aizhi, Scholler, Nathalie, & Coukos, George. (2018). Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunology, Immunotherapy : CII, 67(2), 329–339. https://doi.org/10.1007/s00262-017-2101-0

Blatt, Adam Z., Saggu, Gurpanna, Cortes, Claudio, Herbert, Andrew P., Kavanagh, David, Ricklin, Daniel, Lambris, John D., & Ferreira, Viviana P. (2017). Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. Frontiers in Immunology, 8, 1586. https://doi.org/10.3389/fimmu.2017.01586

Devaurs, Didier, Antunes, Dinler A., Papanastasiou, Malvina, Moll, Mark, Ricklin, Daniel, Lambris, John D., & Kavraki, Lydia E. (2017). Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data. Frontiers in Molecular Biosciences, 4, 13. https://doi.org/10.3389/fmolb.2017.00013

Hajishengallis, George, Reis, Edimara S., Mastellos, Dimitrios C., Ricklin, Daniel, & Lambris, John D. (2017). Novel mechanisms and functions of complement. Nature Immunology, 18(12), 1288–1298. https://doi.org/10.1038/ni.3858

Harder, Markus J., Kuhn, Nadine, Schrezenmeier, Hubert, Höchsmann, Britta, von Zabern, Inge, Weinstock, Christof, Simmet, Thomas, Ricklin, Daniel, Lambris, John D., Skerra, Arne, Anliker, Markus, & Schmidt, Christoph Q. (2017). Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood, 129(8), 970–980. https://doi.org/10.1182/blood-2016-08-732800

Mastellos, Dimitrios C., Reis, Edimara S., Ricklin, Daniel, Smith, Richard J., & Lambris, John D. (2017). Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 38(6), 383–394. https://doi.org/10.1016/j.it.2017.03.003

Papanastasiou, Malvina, Koutsogiannaki, Sophia, Sarigiannis, Yiannis, Geisbrecht, Brian V., Ricklin, Daniel, & Lambris, John D. (2017). Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. Journal of Immunology (Baltimore, Md. : 1950), 198(8), 3326–3335. https://doi.org/10.4049/jimmunol.1601864

Primikyri, Alexandra, Papanastasiou, Malvina, Sarigiannis, Yiannis, Koutsogiannaki, Sophia, Reis, Edimara S., Tuplano, Joel V., Resuello, Ranillo R. G., Nilsson, Bo, Ricklin, Daniel, & Lambris, John D. (2017). Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. Journal of Chromatography B, 1041-1042, 19–26. https://doi.org/10.1016/j.jchromb.2016.12.004

Ricklin, Daniel, Barratt-Due, Andreas, & Mollnes, Tom Eirik. (2017). Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Molecular Immunology, 89, 10–21. https://doi.org/10.1016/j.molimm.2017.05.013

Wang, HongBin, Ricklin, Daniel, & Lambris, John D. (2017). Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proceedings of the National Academy of Sciences of the United States of America, 114(41), 10948–10953. https://doi.org/10.1073/pnas.1707364114

Xue, Xiaoguang, Wu, Jin, Ricklin, Daniel, Forneris, Federico, Di Crescenzio, Patrizia, Schmidt, Christoph Q., Granneman, Joke, Sharp, Thomas H., Lambris, John D., & Gros, Piet. (2017). Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nature Structural and Molecular Biology, 24(8), 643–651. https://doi.org/10.1038/nsmb.3427

Yuan, Xiaopeng, Yang, Mingjuan, Chen, Xiang, Zhang, Xuhua, Sukhadia, Shrey, Musolino, Najia, Bao, Huijing, Chen, Tingtao, Xu, Chen, Wang, Qirui, Santoro, Stephen, Ricklin, Daniel, Hu, Jia, Lin, Ruihe, Yang, Wei, Li, Zhijun, Qin, Weijun, & Zhao, Aizhi. (2017). Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunology, Immunotherapy, 66(3), 367–378. https://doi.org/10.1007/s00262-016-1937-z

Lindorfer, M. A., Cook, E. M., Reis, E. S., Ricklin, D., Risitano, A. M., Lambris, J. D., & Taylor, R. P. (2016). Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 171, 32–35. https://doi.org/10.1016/j.clim.2016.08.017

Mastellos, D. C., Reis, E. S., Yancopoulou, D., Hajishengallis, G., Ricklin, D., & Lambris, J. D. (2016). From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 221(10), 1046–1057. https://doi.org/10.1016/j.imbio.2016.06.013

Ricklin, D., Reis, E. S., & Lambris, J. D. (2016). Complement in disease: a defence system turning offensive. Nature Reviews Nephrology, 12(7), 383–401. https://doi.org/10.1038/nrneph.2016.70

Blatt, A. Z., Saggu, G., Kulkarni, K. V., Cortes, C., Thurman, J. M., Ricklin, D., Lambris, J. D., Valenzuela, J. G., & Ferreira, V. P. (2016). Properdin-mediated c5a production enhances stable binding of platelets to granulocytes in human whole blood. Journal of Immunology, 196(11), 4671–4680. https://doi.org/10.4049/jimmunol.1600040

Hajishengallis, G., Hajishengallis, E., Kajikawa, T., Wang, B., Yancopoulou, D., Ricklin, D., & Lambris, J. D. (2016). Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Seminars in Immunology, 28(3), 285–291. https://doi.org/10.1016/j.smim.2016.03.006

Ricklin, D., & Lambris, J. D. (2016). New milestones ahead in complement-targeted therapy. Seminars in Immunology, 28(3), 208–222. https://doi.org/10.1016/j.smim.2016.06.001

Ricklin, D., & Lambris, J. D. (2016). Complement therapeutics. Seminars in Immunology, 28(3), 205–207. https://doi.org/10.1016/j.smim.2016.07.001

Ricklin, D., & Lambris, J. D. (2016). Therapeutic control of complement activation at the level of the central component C3. Immunobiology, 221(6), 740–746. https://doi.org/10.1016/j.imbio.2015.06.012

Forneris, F., Wu, J., Xue, X., Ricklin, D., Lin, Z., Sfyroera, G., Tzekou, A., Volokhina, E., Granneman, J. C. M., Hauhart, R., Bertram, P., Liszewski, M. K., Atkinson, J. P., Lambris, J. D., & Gros, P. (2016). Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO Journal, 35(10), 1133–1149. https://doi.org/10.15252/embj.201593673

Schmidt, C. Q., Harder, M. J., Nichols, E.-M., Hebecker, M., Anliker, M., Höchsmann, B., Simmet, T., Csincsi, Á. I., Uzonyi, B., Pappworth, I. Y., Ricklin, D., Lambris, J. D., Schrezenmeier, H., Józsi, M., & Marchbank, K. J. (2016). Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 221(4), 503–511. https://doi.org/10.1016/j.imbio.2015.12.009

Maekawa, T., Briones, R. A., Resuello, R. R. G., Tuplano, J. V., Hajishengallis, E., Kajikawa, T., Koutsogiannaki, S., Garcia, C. A. G., Ricklin, D., Lambris, J. D., & Hajishengallis, G. (2016). Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. Journal of Clinical Periodontology, 43(3), 238–249. https://doi.org/10.1111/jcpe.12507

Mastellos, D.C., Ricklin, D., Hajishengallis, E., Hajishengallis, G., & Lambris, J.D. (2016). Complement therapeutics in inflammatory diseases: Promising drug candidates for C3-targeted intervention. Molecular Oral Microbiology, 31(1), 3–17. https://doi.org/10.1111/omi.12129

Harder, M. J., Anliker, M., Ho-Nchsmann, B., Simmet, T., Huber-Lang, M., Schrezenmeier, H., Ricklin, D., Lambris, J. D., Barlow, P. N., & Schmidt, C. Q. (2016). Comparative analysis of novel complement-targeted inhibitors, MiniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of complement regulation. Journal of Immunology, 196(2), 866–876. https://doi.org/10.4049/jimmunol.1501919

Ricklin, Daniel, & Lambris, John D. (2016). Preformed mediators of defense-Gatekeepers enter the spotlight. Immunological Reviews, 274(1), 5–8. https://doi.org/10.1111/imr.12497

Ricklin, Daniel, Reis, Edimara S., Mastellos, Dimitrios C., Gros, Piet, & Lambris, John D. (2016). Complement component C3 - The “Swiss Army Knife” of innate immunity and host defense. Immunological Reviews, 274(1), 33–58. https://doi.org/10.1111/imr.12500

Schmidt, Christoph Q., Lambris, John D., & Ricklin, Daniel. (2016). Protection of host cells by complement regulators. Immunological Reviews, 274(1), 152–171. https://doi.org/10.1111/imr.12475

Wang, J., Wang, L., Xiang, Y., Ricklin, D., Lambris, J. D., & Chen, G. (2016). Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clinical Immunology, 162, 37–44. https://doi.org/10.1016/j.clim.2015.11.002

Reis, E. S., Mastellos, D. C., Yancopoulou, D., Risitano, A. M., Ricklin, D., & Lambris, J. D. (2015). Applying complement therapeutics to rare diseases. Clinical Immunology, 161(2), 225–240. https://doi.org/10.1016/j.clim.2015.08.009

Georgoutsou-Spyridonos, M., Ricklin, D., Pratsinis, H., Perivolioti, E., Pirmettis, I., Garcia, B. L., Geisbrecht, B. V., Foukas, P. G., Lambris, J. D., Mastellos, D. C., & Sfyroera, G. (2015). Attenuation of Staphylococcus aureus-induced bacteremia by human mini-antibodies targeting the complement inhibitory protein Efb. Journal of Immunology, 195(8), 3946–3958. https://doi.org/10.4049/jimmunol.1500966

Lin, Z., Schmidt, C. Q., Koutsogiannaki, S., Ricci, P., Risitano, A. M., Lambris, J. D., & Ricklin, D. (2015). Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria. Blood, 126(7), 891–894. https://doi.org/10.1182/blood-2015-02-625871

Zhang, Y., Shao, D., Ricklin, D., Hilkin, B. M., Nester, C. M., Lambris, J. D., & Smith, R. J. H. (2015). Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology, 220(8), 993–998. https://doi.org/10.1016/j.imbio.2015.04.001

Mastellos, D. C., Yancopoulou, D., Kokkinos, P., Huber-Lang, M., Hajishengallis, G., Biglarnia, A. R., Lupu, F., Nilsson, B., Risitano, A. M., Ricklin, D., & Lambris, J. D. (2015). Compstatin: A C3-targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation, 45(4), 423–440. https://doi.org/10.1111/eci.12419

Reis, E. S., DeAngelis, R. A., Chen, H., Resuello, R. R. G., Ricklin, D., & Lambris, J. D. (2015). Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology, 220(4), 476–482. https://doi.org/10.1016/j.imbio.2014.10.026

Sfyroera, G., Ricklin, D., Reis, E. S., Chen, H., Wu, E. L., Kaznessis, Y. N., Ekdahl, K. N., Nilsson, B., & Lambris, J. D. (2015). Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. Journal of Immunology, 194(7), 3305–3316. https://doi.org/10.4049/jimmunol.1402781

Rafail, S., Kourtzelis, I., Foukas, P. G., Markiewski, M. M., DeAngelis, R. A., Guariento, M., Ricklin, D., Grice, E. A., & Lambris, J. D. (2015). Complement deficiency promotes cutaneous wound healing in mice. Journal of Immunology, 194(3), 1285–1291. https://doi.org/10.4049/jimmunol.1402354

Hamad, O. A., Mitroulis, I., Fromell, K., Kozarcanin, H., Chavakis, T., Ricklin, D., Lambris, J. D., Ekdahl, K. N., & Nilsson, B. (2015). Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thrombosis and Haemostasis, 114(6), 1207–1217. https://doi.org/10.1160/th15-02-0162

Kourtzelis, I., Ferreira, A., Mitroulis, I., Ricklin, D., Bornstein, S.R., Waskow, C., Lambris, J.D., & Chavakis, T. (2015). Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. Hormone and Metabolic Research, 47(1), 36–42. https://doi.org/10.1055/s-0034-1390452

Woehl, J. L., Stapels, D. A. C., Garcia, B. L., Ramyar, K. X., Keightley, A., Ruyken, M., Syriga, M., Sfyroera, G., Weber, A. B., Zolkiewski, M., Ricklin, D., Lambris, J. D., Rooijakkers, S. H. M., & Geisbrecht, B. V. (2014). The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase. Journal of Immunology, 193(12), 6161–6171. https://doi.org/10.4049/jimmunol.1401600

Huang, Y., Reis, E. S., Knerr, P. J., van der Donk, W. A., Ricklin, D., & Lambris, J. D. (2014). Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. ChemMedChem, 9(10), 2223–2226. https://doi.org/10.1002/cmdc.201402212

Mastellos, D. C., Ricklin, D., Yancopoulou, D., Risitano, A., & Lambris, J. D. (2014). Complement in paroxysmal nocturnal hemoglobinuria: Exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 7(5), 583–598. https://doi.org/10.1586/17474086.2014.953926

Maekawa, T., Abe, T., Hajishengallis, E., Hosur, K. B., De Angelis, R. A., Ricklin, D., Lambris, J. D., & Hajishengallis, G. (2014). Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. Journal of Immunology, 192(12), 6020–6027. https://doi.org/10.4049/jimmunol.1400569

Klapper, Y., Hamad, O. A., Teramura, Y., Leneweit, G., Nienhaus, G. U., Ricklin, D., Lambris, J. D., Ekdahl, K. N., & Nilsson, B. (2014). Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials, 35(11), 3688–3696. https://doi.org/10.1016/j.biomaterials.2013.12.085

Risitano, A. M., Ricklin, D., Huang, Y., Reis, E. S., Chen, H., Ricci, P., Lin, Z., Pascariello, C., Raia, M., Sica, M., Del Vecchio, L., Pane, F., Lupu, F., Notaro, R., Resuello, R. R. G., DeAngelis, R. A., & Lambris, J. D. (2014). Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 123(13), 2094–2101. https://doi.org/10.1182/blood-2013-11-536573

Oikonomopoulou, K., Deangelis, R. A., Chen, H., Diamandis, E. P., Hollenberg, M. D., Ricklin, D., & Lambris, J. D. (2013). Induction of complement C3a receptor responses by kallikrein-related peptidase 14. Journal of Immunology, 191(7), 3858–3866. https://doi.org/10.4049/jimmunol.1202999

Ricklin, D., & Cines, D. B. (2013). TMA: Beware of complements. Blood, 122(12), 1997–1999. https://doi.org/10.1182/blood-2013-07-512707

Kourtzelis, I., Rafail, S., DeAngelis, R. A., Foukas, P. G., Ricklin, D., & Lambris, J. D. (2013). Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. FASEB Journal, 27(7), 2768–2776. https://doi.org/10.1096/fj.12-225888

Schmidt, C. Q., Bai, H., Lin, Z., Risitano, A. M., Barlow, P. N., Ricklin, D., & Lambris, J. D. (2013). Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. Journal of Immunology, 190(11), 5712–5721. https://doi.org/10.4049/jimmunol.1203548

Ricklin, D., & Lambris, J. D. (2013). Complement in immune and inflammatory disorders: Pathophysiological mechanisms. Journal of Immunology, 190(8), 3831–3838. https://doi.org/10.4049/jimmunol.1203487

Ricklin, D., & Lambris, J. D. (2013). Complement in immune and inflammatory disorders: Therapeutic interventions. Journal of Immunology, 190(8), 3839–3847. https://doi.org/10.4049/jimmunol.1203200

Qu, H., Ricklin, D., Bai, H., Chen, H., Reis, E. S., Maciejewski, M., Tzekou, A., DeAngelis, R. A., Resuello, R. R. G., Lupu, F., Barlow, P. N., & Lambris, J. D. (2013). New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology, 218(4), 496–505. https://doi.org/10.1016/j.imbio.2012.06.003

Garcia, B. L., Summers, B. J., Ramyar, K. X., Tzekou, A., Lin, Z., Ricklin, D., Lambris, J. D., Laity, J. H., & Geisbrecht, B. V. (2013). A structurally dynamic n-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins. Journal of Biological Chemistry, 288(4), 2870–2881. https://doi.org/10.1074/jbc.m112.426858

Lambris, J. D., Holers, V. M., & Ricklin, D. (2013). Preface. Advances in Experimental Medicine and Biology, 735. https://doi.org/10.1016/j.imbio.2012.07.025

Nilsson, P. H., Ekdahl, K. N., Magnusson, P. U., Qu, H., Iwata, H., Ricklin, D., Hong, J., Lambris, J. D., Nilsson, B., & Teramura, Y. (2013). Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials, 34(4), 985–994. https://doi.org/10.1016/j.biomaterials.2012.10.040

Ricklin, D., & Lambris, J. D. (2013). Progress and trends in complement therapeutics. Advances in Experimental Medicine and Biology, 734, 1–22. https://doi.org/10.1007/978-1-4614-4118-2_1

Abe, T., Hosur, K. B., Hajishengallis, E., Reis, E. S., Ricklin, D., Lambris, J. D., & Hajishengallis, G. (2012). Local complement-targeted intervention in periodontitis: Proof-of-concept using a C5a receptor (CD88) antagonist. Journal of Immunology, 189(11), 5442–5448. https://doi.org/10.4049/jimmunol.1202339

Reis, E. S., Chen, H., Sfyroera, G., Monk, P. N., Köhl, J., Ricklin, D., & Lambris, J. D. (2012). C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: Insights from a novel label-free cellular assay. Journal of Immunology, 189(10), 4797–4805. https://doi.org/10.4049/jimmunol.1200834